Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1)
- 2 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cellular and Molecular Life Sciences
- Vol. 77 (17), 3351-3367
- https://doi.org/10.1007/s00018-020-03492-0
Abstract
Spinal muscular atrophy (SMA) with respiratory distress type 1 (SMARD1) is an autosomal recessive motor neuron disease that is characterized by distal and proximal muscle weakness and diaphragmatic palsy that leads to respiratory distress. Without intervention, infants with the severe form of the disease die before 2 years of age. SMARD1 is caused by mutations in the IGHMBP2 gene that determine a deficiency in the encoded IGHMBP2 protein, which plays a critical role in motor neuron survival because of its functions in mRNA processing and maturation. Although it is rare, SMARD1 is the second most common motor neuron disease of infancy, and currently, treatment is primarily supportive. No effective therapy is available for this devastating disease, although multidisciplinary care has been an essential element of the improved quality of life and life span extension in these patients in recent years. The objectives of this review are to discuss the current understanding of SMARD1 through a summary of the presently known information regarding its clinical presentation and pathogenesis and to discuss emerging therapeutic approaches. Advances in clinical care management have significantly extended the lives of individuals affected by SMARD1 and research into the molecular mechanisms that lead to the disease has identified potential strategies for intervention that target the underlying causes of SMARD1. Gene therapy via gene replacement or gene correction provides the potential for transformative therapies to halt or possibly prevent neurodegenerative disease in SMARD1 patients. The recent approval of the first gene therapy approach for SMA associated with mutations in the SMN1 gene may be a turning point for the application of this strategy for SMARD1 and other genetic neurological diseases.Keywords
Funding Information
- Ministero della Salute (GR-2016-02362377)
- Fondazione Cariplo
This publication has 113 references indexed in Scilit:
- Astrocytes from familial and sporadic ALS patients are toxic to motor neuronsNature Biotechnology, 2011
- Human Senataxin Resolves RNA/DNA Hybrids Formed at Transcriptional Pause Sites to Promote Xrn2-Dependent TerminationMolecular Cell, 2011
- Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALSNature, 2010
- Stem Cell Model of Spinal Muscular AtrophyArchives of Neurology, 2010
- A Genome-wide siRNA Screen Reveals Diverse Cellular Processes and Pathways that Mediate Genome StabilityMolecular Cell, 2009
- Biochemical and genetic evidence for a role of IGHMBP2 in the translational machineryHuman Molecular Genetics, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophyThe Journal of cell biology, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006